AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Group)

• 11 Inventories
• 12 Trade and other receivables
• 13 Cash and cash equivalents
• 14 Interest bearing loans and borrowings
• 15 Financial risk management objectives and policies

13 Cash and cash equivalents

	2008  $m	2007  $m	2006  $m
Cash at bank and in hand	1,039	1,403	684
Short-term deposits	3,247	4,464	6,419
Cash and cash equivalents	4,286	5,867	7,103
Unsecured bank overdrafts	(163)	(140)	(114)
Cash and cash equivalents in the cash flow statement	4,123	5,727	6,989

The Group’s insurance subsidiaries hold cash and short-term investments totalling $400m (2007: $347m; 2006: $320m), of which $278m (2007: $257m; 2006: $220m) is required to meet insurance solvency requirements and which, as a result, is not readily available for the general purposes of the Group.

Back to the top